Some known conflicts of interest:

http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3663t1.rtf

FOOD AND DRUG ADMINISTRATION

CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH

VACCINES AND RELATED BIOLOGICAL
PRODUCTS ADVISORY COMMITTEE

FRIDAY
NOVEMBER 3, 2000

PRESENT:

ROBERT S. DAUM, M.D.         Acting Chair (recused)
DIANE E. GRIFFIN, M.D., Ph.D.   Acting Chair
PAMELA S. DIAZ, M.D.            Member
MARY K. ESTES, Ph.D.            Member
WALTER L. FAGGETT, M.D.         Member
BARBARA LOE FISHER              Member
THOMAS R. FLEMING               Invited Participant
JUDITH D. GOLDBERG, Sc.D.       Member
ALICE S. HUANG, Ph.D.           Member
ERIK HEWLETT, M.D.              Invited Participant
SAMUEL L. KATZ, M.D.            Member
STEVE KOHL, M.D.                Member
JOHN LIVENGOOD, M.D.            Invited Participant
MARTIN MYERS, M.D.              Invited Participant
AUDREY F. MANLEY, M.D., M.P.H.  Member
DAVID S. STEPHENS, M.D.         Member

And now I will go ahead and read the conflict of interest statement. The following announcement addresses conflict of interest issues associated with the meeting of the Vaccines and Biological Products Advisory Committee on November 3, 2000, for the discussion of the safety and efficacy of CPDT Adsorbed, the Diphtheria Tetanus Acellular Pertussis Vaccine sponsored by Aventis Pasteur Limited of Toronto, Canada.
Of the committee members, Drs. Kim and Snyder could not be with us today.  However, the Director of the Center for Biologics Evaluation and Research has appointed Drs. Thomas Fleming, Erik Hewlett, John Livengood and Martin Myers as temporary voting members for the discussion.  To determine if any conflicts of interest existed, the Agency reviewed the submitted agenda and all financial interests reported by the meeting
participants. As a result of this review, the following disclosures were made.  In accordance with 18 U.S.C. 208, Dr. Goldberg, Kohl, Fleming and Hewlett have been granted waivers which permit them to participate in the committee discussion and to vote.  In accordance with the Food and Drug Administration Modernization Act of 1997, Section 505, Drs. Estes, Goldberg, Kohl, Stephens, Fleming and Hewlett have been granted waivers which permit them to participate fully in the committee discussions. Dr. Robert Daum has recused himself from the discussion on CPDT Adsorbed.  Drs. Estes, Faggett, Griffin, Katz and Stephens have associations with firms that could be affected by the committee discussions. However, in accordance with 18 U.S.C. 208 and Section 2635.502 of the Standards of Conduct, it has been determined that waivers or appearance determinations are not warranted for this discussion.